CN1390141A - 含核酸的复合物 - Google Patents
含核酸的复合物 Download PDFInfo
- Publication number
- CN1390141A CN1390141A CN00815477A CN00815477A CN1390141A CN 1390141 A CN1390141 A CN 1390141A CN 00815477 A CN00815477 A CN 00815477A CN 00815477 A CN00815477 A CN 00815477A CN 1390141 A CN1390141 A CN 1390141A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- biodegradable polymer
- gene
- disease
- positively charged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
目的 | 核酸类型 | |
心血管领域的基因治疗 | 增加血管生成和可用于阻塞性动脉硬化和缺血性心脏病 | ·血管内皮生长因子(VEGF)基因·肝细胞生长因子(HGF)基因·成纤维细胞生长因子(FGF)基因 |
再生血管内皮细胞和可用于防止动脉成形术后的再狭窄 | ·VEGF基因·HGF基因·内皮细胞一氧化氮合成酶基因·PGI2合成基因 | |
调节血管平滑肌细胞的细胞周期和可用于预防动脉成形术或分流手术后的再狭窄 | ·c-myb的反义寡核苷酸·PCNA基因的反义寡核苷酸·cdc-2激酶的反义寡核苷酸 | |
可用于分流手术后的再狭窄的预防等 | ·具有与转录因子E2F结合序列相同的序列的双链核酸化合物·E2F诱饵 | |
可应用于基因治疗缺血-再灌注造成的损伤 | ·NFκB诱饵 | |
癌症的基因治疗 | 自杀基因的转移 | ·单纯疱疹病毒胸苷激酶基因 |
肿瘤抑制基因的转移 | ·p53基因 | |
保护骨髓干细胞免受抗癌药物的作用 | ·广谱抗药(MDR)基因 | |
免疫治疗 | ·白介素12基因·B7基因 | |
反义RNA | ·ras基因 |
Claims (49)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP318187/99 | 1999-11-09 | ||
JP31818799 | 1999-11-09 | ||
JP278878/00 | 2000-09-13 | ||
JP2000278878A JP2001199903A (ja) | 1999-11-09 | 2000-09-13 | 核酸含有複合体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1390141A true CN1390141A (zh) | 2003-01-08 |
CN100417418C CN100417418C (zh) | 2008-09-10 |
Family
ID=26569281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008154775A Expired - Fee Related CN100417418C (zh) | 1999-11-09 | 2000-11-09 | 含核酸的复合物 |
Country Status (11)
Country | Link |
---|---|
US (2) | US7276594B1 (zh) |
EP (1) | EP1229941A2 (zh) |
JP (1) | JP2001199903A (zh) |
KR (1) | KR100873593B1 (zh) |
CN (1) | CN100417418C (zh) |
AU (1) | AU1303401A (zh) |
BR (1) | BR0015419A (zh) |
CA (1) | CA2389506A1 (zh) |
IL (2) | IL149491A0 (zh) |
TW (1) | TWI267380B (zh) |
WO (1) | WO2001034206A2 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1859926B (zh) * | 2003-06-30 | 2011-02-09 | 坎基股份有限公司 | 腺病毒的聚合物包裹 |
WO2012129767A1 (zh) * | 2011-03-28 | 2012-10-04 | 南京大学 | 阳离子修饰的琼脂糖水凝胶和核酸药物组合物及制法和应用 |
CN107849512A (zh) * | 2015-07-24 | 2018-03-27 | 菲布拉利恩公司 | 用于靶向递送基于核酸的疗法的组合物 |
CN111620985B (zh) * | 2019-02-28 | 2023-08-08 | 康码(上海)生物科技有限公司 | 共价固定dna的水凝胶及其应用 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
JP2003516365A (ja) * | 1999-12-08 | 2003-05-13 | フアルマコンセプツ・エイビー | 核酸送達系 |
DE60134021D1 (de) * | 2000-06-27 | 2008-06-26 | Anges Mg Inc | Pharmazeutische zubereitungen zur angiogenese-therapie |
US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
EP1347776A2 (en) * | 2001-01-05 | 2003-10-01 | Intercell Biomedizinische Forschungs- und Entwicklungs AG | Anti-inflammatory use of polycationic compounds |
JP2008067717A (ja) * | 2001-06-20 | 2008-03-27 | Dainippon Sumitomo Pharma Co Ltd | 核酸導入を促進させる方法 |
EP1407787B1 (en) | 2001-06-20 | 2009-04-29 | Dainippon Sumitomo Pharma Co., Ltd. | Method of promoting nucleic acid transfer |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
JP4022614B2 (ja) * | 2002-03-25 | 2007-12-19 | 国立大学法人大阪大学 | 新規なバイオビーズの作製方法 |
AU2003264507A1 (en) * | 2002-09-20 | 2004-04-08 | Koken Co., Ltd. | Site-specific gene conversion promoter and gene therapeutic |
KR100514092B1 (ko) * | 2002-11-23 | 2005-09-13 | 한국생명공학연구원 | 양이온성 고분자 물질과 음이온성 고분자 물질을 이용한 새로운 다중 유전자 전달 복합체 |
MXPA05006193A (es) * | 2002-12-11 | 2005-12-05 | Ferrosan As | Materiales basados en gelatina como hisopos. |
JPWO2004078213A1 (ja) * | 2003-03-06 | 2006-06-08 | 千佳子 錦織 | 対象物質導入用組成物及び対象物質導入方法 |
WO2005094894A1 (ja) * | 2004-03-31 | 2005-10-13 | Medgel Corporation | 細胞に核酸を導入するための製剤 |
JP4767195B2 (ja) * | 2004-08-27 | 2011-09-07 | ネオケミア株式会社 | 核酸皮膚外用製剤 |
JP2007182407A (ja) * | 2006-01-10 | 2007-07-19 | Medgel Corp | 徐放性ハイドロゲル製剤 |
CN1936011B (zh) * | 2006-10-17 | 2011-12-07 | 浙江医药高等专科学校 | 聚阳离子脂质体端粒酶反义寡核苷酸复合物及制备 |
CN102014973A (zh) | 2008-02-29 | 2011-04-13 | 弗罗桑医疗设备公司 | 用于促进止血和/或伤口愈合的装置 |
JP2009227641A (ja) * | 2008-03-25 | 2009-10-08 | Takahiko Saito | ステント |
EP2822474B1 (en) | 2012-03-06 | 2018-05-02 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
BR112014030962A2 (pt) | 2012-06-12 | 2017-06-27 | Ferrosan Medical Devices As | métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
EP3470094B1 (en) | 2013-12-11 | 2020-07-22 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
WO2016058612A1 (en) | 2014-10-13 | 2016-04-21 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
WO2016102446A1 (en) | 2014-12-24 | 2016-06-30 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
EP3265112A4 (en) * | 2015-01-19 | 2018-10-03 | Rappaport Family Institute For Research In The Medical Sciences | Ubiquitin ligase kpc1 promotes processing of p105 nf-kappab1 to p50, eliciting strong tumor suppression |
WO2017005590A1 (en) | 2015-07-03 | 2017-01-12 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
WO2018186531A1 (ko) * | 2017-04-03 | 2018-10-11 | 선진뷰티사이언스(주) | 액적 방출 화장료 |
EP4321182A2 (en) | 2018-05-09 | 2024-02-14 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294249A (en) * | 1987-03-27 | 1994-03-15 | Luisi Pier L | Blendpolymers |
US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
AU2946295A (en) * | 1994-06-27 | 1996-01-19 | Johns Hopkins University, The | Targeted gene delivery system |
WO1996000079A1 (en) * | 1994-06-27 | 1996-01-04 | The General Hospital Corporation | Graft co-polymer adducts of platinum (ii) compounds |
US5972707A (en) * | 1994-06-27 | 1999-10-26 | The Johns Hopkins University | Gene delivery system |
US6565842B1 (en) * | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
US6184037B1 (en) * | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
-
2000
- 2000-09-13 JP JP2000278878A patent/JP2001199903A/ja active Pending
- 2000-11-08 TW TW089123586A patent/TWI267380B/zh not_active IP Right Cessation
- 2000-11-09 CN CNB008154775A patent/CN100417418C/zh not_active Expired - Fee Related
- 2000-11-09 IL IL14949100A patent/IL149491A0/xx active IP Right Grant
- 2000-11-09 US US10/129,906 patent/US7276594B1/en not_active Expired - Fee Related
- 2000-11-09 WO PCT/JP2000/007882 patent/WO2001034206A2/en active Application Filing
- 2000-11-09 EP EP00974862A patent/EP1229941A2/en not_active Withdrawn
- 2000-11-09 CA CA002389506A patent/CA2389506A1/en not_active Abandoned
- 2000-11-09 AU AU13034/01A patent/AU1303401A/en not_active Abandoned
- 2000-11-09 BR BR0015419-9A patent/BR0015419A/pt not_active Application Discontinuation
- 2000-11-09 KR KR1020027006003A patent/KR100873593B1/ko not_active IP Right Cessation
-
2002
- 2002-05-06 IL IL149491A patent/IL149491A/en not_active IP Right Cessation
-
2007
- 2007-04-25 US US11/740,200 patent/US20090203768A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1859926B (zh) * | 2003-06-30 | 2011-02-09 | 坎基股份有限公司 | 腺病毒的聚合物包裹 |
WO2012129767A1 (zh) * | 2011-03-28 | 2012-10-04 | 南京大学 | 阳离子修饰的琼脂糖水凝胶和核酸药物组合物及制法和应用 |
CN107849512A (zh) * | 2015-07-24 | 2018-03-27 | 菲布拉利恩公司 | 用于靶向递送基于核酸的疗法的组合物 |
CN107849512B (zh) * | 2015-07-24 | 2023-01-13 | 菲布拉利恩公司 | 用于靶向递送基于核酸的疗法的组合物 |
CN111620985B (zh) * | 2019-02-28 | 2023-08-08 | 康码(上海)生物科技有限公司 | 共价固定dna的水凝胶及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2001034206A8 (en) | 2001-07-26 |
CN100417418C (zh) | 2008-09-10 |
KR100873593B1 (ko) | 2008-12-11 |
US20090203768A1 (en) | 2009-08-13 |
EP1229941A2 (en) | 2002-08-14 |
US7276594B1 (en) | 2007-10-02 |
WO2001034206A3 (en) | 2002-02-07 |
IL149491A (en) | 2008-04-13 |
CA2389506A1 (en) | 2001-05-17 |
AU1303401A (en) | 2001-06-06 |
JP2001199903A (ja) | 2001-07-24 |
IL149491A0 (en) | 2002-11-10 |
WO2001034206A2 (en) | 2001-05-17 |
KR20020060733A (ko) | 2002-07-18 |
BR0015419A (pt) | 2002-07-02 |
TWI267380B (en) | 2006-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1390141A (zh) | 含核酸的复合物 | |
Xiao et al. | Engineering nanoparticles for targeted delivery of nucleic acid therapeutics in tumor | |
Lee et al. | Bioreducible polymers for therapeutic gene delivery | |
Xie et al. | Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells | |
CN108542885B (zh) | 抗肿瘤药物及其制备方法 | |
Dosta et al. | Delivery of anti‐microRNA‐712 to inflamed endothelial cells using poly (β‐amino ester) nanoparticles conjugated with VCAM‐1 targeting peptide | |
Xie et al. | Immunoengineering with biomaterials for enhanced cancer immunotherapy | |
US20030138407A1 (en) | Therapeutic methods for nucleic acid delivery vehicles | |
ES2907486T3 (es) | Métodos y composiciones para reducir metástasis | |
CN1893924A (zh) | 一种新的阳离子脂质聚合物作为生物相容性基因递送剂 | |
JP5294858B2 (ja) | 生理活性ポリペプチドまたはタンパク質内包高分子ポリマーミセルおよびその製造方法 | |
WO2008058457A1 (fr) | Polyéthylèneimine réticulé biodégradable et ses utilisations | |
CN106177975A (zh) | 具有不对称膜结构的可逆交联生物可降解聚合物囊泡及其制备方法与在核酸药物中的应用 | |
JP2024016040A (ja) | 去勢抵抗性前立腺癌 | |
Karim et al. | Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment | |
WO2012142292A2 (en) | Biofunctionalized polymer microparticles for biotherapeutic delivery and processes for using and making the same | |
CN108126210A (zh) | 一种单靶向还原响应囊泡纳米药物在制备脑肿瘤治疗药物中的应用 | |
CN117384859B (zh) | 一种树突状细胞来源的外泌体的制备方法及应用 | |
Ogris | Nucleic acid based therapeutics for tumor therapy | |
US20020137670A1 (en) | Transferrin polycation/DNA complexes for the systemic treatment of tumor diseases with cytotoxic proteins | |
Chen et al. | Revitalizing Cytokine‐Based Cancer Immunotherapy through Advanced Delivery Systems | |
Li et al. | Advanced Materials and Delivery Systems for Enhancement of Chimeric Antigen Receptor Cells | |
CN114917357B (zh) | 转铁蛋白导向的装载plk1抑制剂的聚合物囊泡及其制备方法与应用 | |
CN114470237B (zh) | 一种类病毒结构基因载体、药物递送系统、其制备方法及其应用 | |
Wilson | Polymeric Nanoparticle Engineering for Delivery of Nucleic Acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIAN YASUHIKO Effective date: 20040716 Owner name: SHENG YINGSAN Free format text: FORMER OWNER: CMIC CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20040716 Address after: Tokyo, Japan, Japan Applicant after: Sheng Yingsan Co-applicant after: Yasuhiko Tabata Address before: Tokyo, Japan Applicant before: CMIC Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080910 Termination date: 20101109 |